Search

Your search keyword '"Bhoopathi, Praveen"' showing total 228 results
Start Over Author "Bhoopathi, Praveen" Publication Year Range Last 10 years
228 results on '"Bhoopathi, Praveen"'

1. Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β

Author

Pradhan, Anjan K, Maji, Santanu, Bhoopathi, Praveen, Talukdar, Sarmistha, Mannangatti, Padmanabhan, Guo, Chunqing, Wang, Xiang-Yang, Cartagena, Lorraine Colon, Idowu, Michael, Landry, Joseph W, Sarkar, Devanand, Emdad, Luni, Cavenee, Webster K, Das, Swadesh K, and Fisher, Paul B

Subjects
Breast Cancer, Genetics, Cancer, Aetiology, 2.1 Biological and endogenous factors, Animals, Antineoplastic Agents, Breast Neoplasms, Cell Line, Tumor, Chemokine CCL11, Chemokine CCL17, Female, Gene Expression Regulation, Neoplastic, Humans, Interleukin-10, Interleukin-1alpha, Interleukin-1beta, Interleukin-23 Subunit p19, Interleukin-5, Lung Neoplasms, Mice, Mice, Inbred BALB C, Oxadiazoles, Pyrimidines, Signal Transduction, Syntenins, T-Lymphocytes, Cytotoxic, Tumor Burden, Xenograft Model Antitumor Assays, metastasis, breast cancer, MDA-9, Syntenin, IL-1 beta, IL-1β, MDA-9/Syntenin
Abstract

Melanoma differentiation associated gene-9 (MDA-9), Syntenin-1, or syndecan binding protein is a differentially regulated prometastatic gene with elevated expression in advanced stages of melanoma. MDA-9/Syntenin expression positively associates with advanced disease stage in multiple histologically distinct cancers and negatively correlates with patient survival and response to chemotherapy. MDA-9/Syntenin is a highly conserved PDZ-domain scaffold protein, robustly expressed in a spectrum of diverse cancer cell lines and clinical samples. PDZ domains interact with a number of proteins, many of which are critical regulators of signaling cascades in cancer. Knockdown of MDA-9/Syntenin decreases cancer cell metastasis, sensitizing these cells to radiation. Genetic silencing of MDA-9/Syntenin or treatment with a pharmacological inhibitor of the PDZ1 domain, PDZ1i, also activates the immune system to kill cancer cells. Additionally, suppression of MDA-9/Syntenin deregulates myeloid-derived suppressor cell differentiation via the STAT3/interleukin (IL)-1β pathway, which concomitantly promotes activation of cytotoxic T lymphocytes. Biologically, PDZ1i treatment decreases metastatic nodule formation in the lungs, resulting in significantly fewer invasive cancer cells. In summary, our observations indicate that MDA-9/Syntenin provides a direct therapeutic target for mitigating aggressive breast cancer and a small-molecule inhibitor, PDZ1i, provides a promising reagent for inhibiting advanced breast cancer pathogenesis.

Published
2021

3. MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF

Author

Pradhan, Anjan K, Bhoopathi, Praveen, Talukdar, Sarmistha, Scheunemann, Danielle, Sarkar, Devanand, Cavenee, Webster K, Das, Swadesh K, Emdad, Luni, and Fisher, Paul B

Subjects
Genetics, Urologic Diseases, Biotechnology, Cancer, Prostate Cancer, 2.1 Biological and endogenous factors, Aetiology, Animals, Apoptosis, Cell Differentiation, Cell Line, Tumor, Cell Proliferation, DEAD-box RNA Helicases, Down-Regulation, Genes, Tumor Suppressor, Humans, Interleukins, Male, Mice, Mice, Nude, MicroRNAs, Microphthalmia-Associated Transcription Factor, Neoplasms, Prostatic Neoplasms, Reactive Oxygen Species, Ribonuclease III, Signal Transduction, Xenograft Model Antitumor Assays, mda-7/IL-24, miRNA, ROS, DICER, MITF
Abstract

Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) is a multifunctional cytokine displaying broad-spectrum anticancer activity in vitro or in vivo in preclinical animal cancer models and in a phase 1/2 clinical trial in patients with advanced cancers. mda-7/IL-24 targets specific miRNAs, including miR-221 and miR-320, for down-regulation in a cancer-selective manner. We demonstrate that mda-7/IL-24, administered through a replication incompetent type 5 adenovirus (Ad.mda-7) or with His-MDA-7/IL-24 protein, down-regulates DICER, a critical regulator in miRNA processing. This effect is specific for mature miR-221, as it does not affect Pri-miR-221 expression, and the DICER protein, as no changes occur in other miRNA processing cofactors, including DROSHA, PASHA, or Argonaute. DICER is unchanged by Ad.mda-7/IL-24 in normal immortal prostate cells, whereas Ad.mda-7 down-regulates DICER in multiple cancer cells including glioblastoma multiforme and prostate, breast, lung, and liver carcinoma cells. MDA-7/IL-24 protein down-regulates DICER expression through canonical IL-20/IL-22 receptors. Gain- and loss-of-function studies confirm that overexpression of DICER rescues deregulation of miRNAs by mda-7/IL-24, partially rescuing cancer cells from mda-7/IL-24-mediated cell death. Stable overexpression of DICER in cancer cells impedes Ad.mda-7 or His-MDA-7/IL-24 inhibition of cell growth, colony formation, PARP cleavage, and apoptosis. In addition, stable overexpression of DICER renders cancer cells more resistant to Ad.mda-7 inhibition of primary and secondary tumor growth. MDA-7/IL-24-mediated regulation of DICER is reactive oxygen species-dependent and mediated by melanogenesis-associated transcription factor. Our research uncovers a distinct role of mda-7/IL-24 in the regulation of miRNA biogenesis through alteration of the MITF-DICER pathway.

Published
2019

4. Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus.

Author

Bhoopathi, Praveen, Mannangatti, Padmanabhan, Pradhan, Anjan K., Kumar, Amit, Maji, Santanu, Lang, Frederick F., Klibanov, Alexander L., Madan, Esha, Cavenee, Webster K., Keoprasert, Timothy, Sun, Dong, Bjerkvig, Rolf, Thorsen, Frits, Gogna, Rajan, Das, Swadesh K., Emdad, Luni, and Fisher, Paul B.

Subjects
*SECONDARY primary cancer, *BRAIN tumors, *BRAIN cancer, *THERAPEUTICS, *ONCOGENIC viruses, *VIRAL tropism
Abstract

Primary, glioblastoma, and secondary brain tumors, from metastases outside the brain, are among the most aggressive and therapeutically resistant cancers. A physiological barrier protecting the brain, the blood–brain barrier (BBB), functions as a deterrent to effective therapies. To enhance cancer therapy, we developed a cancer terminator virus (CTV), a unique tropism‐modified adenovirus consisting of serotype 3 fiber knob on an otherwise Ad5 capsid that replicates in a cancer‐selective manner and simultaneously produces a potent therapeutic cytokine, melanoma differentiation‐associated gene‐7/interleukin‐24 (MDA‐7/IL‐24). A limitation of the CTV and most other viruses, including adenoviruses, is an inability to deliver systemically to treat brain tumors because of the BBB, nonspecific virus trapping, and immune clearance. These obstacles to effective viral therapy of brain cancer have now been overcome using focused ultrasound with a dual microbubble treatment, the focused ultrasound‐double microbubble (FUS‐DMB) approach. Proof‐of‐principle is now provided indicating that the BBB can be safely and transiently opened, and the CTV can then be administered in a second set of complement‐treated microbubbles and released in the brain using focused ultrasound. Moreover, the FUS‐DMB can be used to deliver the CTV multiple times in animals with glioblastoma growing in their brain thereby resulting in a further enhancement in survival. This strategy permits efficient therapy of primary and secondary brain tumors enhancing animal survival without promoting harmful toxic or behavioral side effects. Additionally, when combined with a standard of care therapy, Temozolomide, a further increase in survival is achieved. The FUS‐DMB approach with the CTV highlights a noninvasive strategy to treat brain cancers without surgery. This innovative delivery scheme combined with the therapeutic efficacy of the CTV provides a novel potential translational therapeutic approach for brain cancers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells

Author

Talukdar, Sarmistha, Pradhan, Anjan K, Bhoopathi, Praveen, Shen, Xue-Ning, August, Laura A, Windle, Jolene J, Sarkar, Devanand, Furnari, Frank B, Cavenee, Webster K, Das, Swadesh K, Emdad, Luni, and Fisher, Paul B

Subjects
Rare Diseases, Cancer, Brain Cancer, Stem Cell Research, Brain Disorders, Anoikis, Autophagy, Brain Neoplasms, Drug Resistance, Neoplasm, Glioma, Humans, Neoplastic Stem Cells, Syntenins, Tumor Cells, Cultured, glioma stem cells, autophagy, anoikis resistance, MDA-9/Syntenin, cell death
Abstract

Glioma stem cells (GSCs) comprise a small subpopulation of glioblastoma multiforme cells that contribute to therapy resistance, poor prognosis, and tumor recurrence. Protective autophagy promotes resistance of GSCs to anoikis, a form of programmed cell death occurring when anchorage-dependent cells detach from the extracellular matrix. In nonadherent conditions, GSCs display protective autophagy and anoikis-resistance, which correlates with expression of melanoma differentiation associated gene-9/Syntenin (MDA-9) (syndecan binding protein; SDCBP). When MDA-9 is suppressed, GSCs undergo autophagic death supporting the hypothesis that MDA-9 regulates protective autophagy in GSCs under anoikis conditions. MDA-9 maintains protective autophagy through phosphorylation of BCL2 and by suppressing high levels of autophagy through EGFR signaling. MDA-9 promotes these changes by modifying FAK and PKC signaling. Gain-of-function and loss-of-function genetic approaches demonstrate that MDA-9 regulates pEGFR and pBCL2 expression through FAK and pPKC. EGFR signaling inhibits autophagy markers (ATG5, Lamp1, LC3B), helping to maintain protective autophagy, and along with pBCL2 maintain survival of GSCs. In the absence of MDA-9, this protective mechanism is deregulated; EGFR no longer maintains protective autophagy, leading to highly elevated and sustained levels of autophagy and consequently decreased cell survival. In addition, pBCL2 is down-regulated in the absence of MDA-9, leading to cell death in GSCs under conditions of anoikis. Our studies confirm a functional link between MDA-9 expression and protective autophagy in GSCs and show that inhibition of MDA-9 reverses protective autophagy and induces anoikis and cell death in GSCs.

Published
2018

6. Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity

Author

Bhoopathi, Praveen, primary, Kumar, Amit, additional, Pradhan, Anjan K, additional, Maji, Santanu, additional, Mannangatti, Padmanabhan, additional, Windle, Jolene J, additional, Subler, Mark A, additional, Zhang, Dongyu, additional, Vudatha, Vignesh, additional, Trevino, Jose G, additional, Madan, Esha, additional, Atfi, Azeddine, additional, Sarkar, Devanand, additional, Gogna, Rajan, additional, Das, Swadesh K, additional, Emdad, Luni, additional, and Fisher, Paul B, additional

Published
2023
Full Text
View/download PDF

8. Supplementary Fig. S6 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis

Author

Pradhan, Anjan K., primary, Modi, Jinkal, primary, Maji, Santanu, primary, Kumar, Amit, primary, Bhoopathi, Praveen, primary, Mannangatti, Padmanabhan, primary, Guo, Chunqing, primary, Afosah, Daniel K., primary, Mochel, Mark C., primary, Mukhopadhyay, Nitai D., primary, Kirkwood, John M., primary, Wang, Xiang-Yang, primary, Desai, Umesh R., primary, Sarkar, Devanand, primary, Emdad, Luni, primary, Das, Swadesh K., primary, and Fisher, Paul B., primary

Published
2023
Full Text
View/download PDF

9. Data from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis

Author

Pradhan, Anjan K., primary, Modi, Jinkal, primary, Maji, Santanu, primary, Kumar, Amit, primary, Bhoopathi, Praveen, primary, Mannangatti, Padmanabhan, primary, Guo, Chunqing, primary, Afosah, Daniel K., primary, Mochel, Mark C., primary, Mukhopadhyay, Nitai D., primary, Kirkwood, John M., primary, Wang, Xiang-Yang, primary, Desai, Umesh R., primary, Sarkar, Devanand, primary, Emdad, Luni, primary, Das, Swadesh K., primary, and Fisher, Paul B., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Data from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis

Author

Pradhan, Anjan K., primary, Modi, Jinkal, primary, Maji, Santanu, primary, Kumar, Amit, primary, Bhoopathi, Praveen, primary, Mannangatti, Padmanabhan, primary, Guo, Chunqing, primary, Afosah, Daniel K., primary, Mochel, Mark C., primary, Mukhopadhyay, Nitai D., primary, Kirkwood, John M., primary, Wang, Xiang-Yang, primary, Desai, Umesh R., primary, Sarkar, Devanand, primary, Emdad, Luni, primary, Das, Swadesh K., primary, and Fisher, Paul B., primary

Published
2023
Full Text
View/download PDF

11. Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis

Author

Pradhan, Anjan K., primary, Modi, Jinkal, additional, Maji, Santanu, additional, Kumar, Amit, additional, Bhoopathi, Praveen, additional, Mannangatti, Padmanabhan, additional, Guo, Chunqing, additional, Afosah, Daniel K., additional, Mochel, Mark C., additional, Mukhopadhyay, Nitai D., additional, Kirkwood, John M., additional, Wang, Xiang-Yang, additional, Desai, Umesh R., additional, Sarkar, Devanand, additional, Emdad, Luni, additional, Das, Swadesh K., additional, and Fisher, Paul B., additional

Published
2023
Full Text
View/download PDF

14. MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.

Author

Maji, Santanu, Pradhan, Anjan K., Kumar, Amit, Bhoopathi, Praveen, Mannangatti, Padmanabhan, Chunqing Guo, Windle, Jolene J., Subler, Mark A., Xiang-Yang Wang, Semmes, Oliver J., Nyalwidhe, Julius O., Mukhopadhyay, Nitai, Paul, Asit Kr, Hatfield, Bryce, Levit, Michael M., Madan, Esha, Sarkar, Devanand, Emdad, Luni, Cohen, David J., and Gogna, Rajan

Subjects
BONE metastasis, METASTASIS, BONE cancer, TUMOR microenvironment, PROSTATE cancer, POLYMETHYLMETHACRYLATE
Abstract

Bone metastasis is a frequent and incurable consequence of advanced prostate cancer (PC). An interplay between disseminated tumor cells and heterogeneous bone resident cells in the metastatic niche initiates this process. Melanoma differentiation associated gene-9 (mda-9/Syntenin/syndecan binding protein) is a prometastatic gene expressed in multiple organs, including bone marrow-derived mesenchymal stromal cells (BM-MSCs), under both physiological and pathological conditions. We demonstrate that PDGF-AA secreted by tumor cells induces CXCL5 expression in BM-MSCs by suppressing MDA-9-dependent YAP/MST signaling. CXCL5-derived tumor cell proliferation and immune suppression are consequences of the MDA-9/CXCL5 signaling axis, promoting PC disease progression. mda-9 knockout tumor cells express less PDGF-AA and do not develop bone metastases. Our data document a previously undefined role of MDA-9/Syntenin in the tumor and microenvironment in regulating PC bone metastasis. This study provides a framework for translational strategies to ameliorate health complications and morbidity associated with advanced PC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Abstract 3394: Simultaneous targeting of the PDZ1 and PDZ2 domains of MDA-9 inhibits melanoma metastasis

Author

Pradhan, Anjan K., primary, Modi, Jinkal, additional, Maji, Santanu, additional, Kumar, Amit, additional, Bhoopathi, Praveen, additional, Mannangatti, Padmanabhan, additional, Guo, Chunqing, additional, Afosah, Daniel K., additional, Mochel, Mark, additional, Mukhopadhyay, Nitai D., additional, Kirkwood, John M., additional, Wang, Xiang-Yang, additional, Desai, Umesh R., additional, Sarkar, Devanand, additional, Emdad, Luni, additional, Das, Swadesh K., additional, and Fisher, Paul B., additional

Published
2023
Full Text
View/download PDF

23. Data from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells

Author

Chetty, Chandramu, primary, Lakka, Sajani S., primary, Bhoopathi, Praveen, primary, Gondi, Christopher S., primary, Veeravalli, Krishna Kumar, primary, Fassett, Daniel, primary, Klopfenstein, Jeffrey D., primary, Dinh, Dzung H., primary, Gujrati, Meena, primary, and Rao, Jasti S., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 1 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells

Author

Chetty, Chandramu, primary, Lakka, Sajani S., primary, Bhoopathi, Praveen, primary, Gondi, Christopher S., primary, Veeravalli, Krishna Kumar, primary, Fassett, Daniel, primary, Klopfenstein, Jeffrey D., primary, Dinh, Dzung H., primary, Gujrati, Meena, primary, and Rao, Jasti S., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 2 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells

Author

Chetty, Chandramu, primary, Lakka, Sajani S., primary, Bhoopathi, Praveen, primary, Gondi, Christopher S., primary, Veeravalli, Krishna Kumar, primary, Fassett, Daniel, primary, Klopfenstein, Jeffrey D., primary, Dinh, Dzung H., primary, Gujrati, Meena, primary, and Rao, Jasti S., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure Legends from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells

Author

Chetty, Chandramu, primary, Lakka, Sajani S., primary, Bhoopathi, Praveen, primary, Gondi, Christopher S., primary, Veeravalli, Krishna Kumar, primary, Fassett, Daniel, primary, Klopfenstein, Jeffrey D., primary, Dinh, Dzung H., primary, Gujrati, Meena, primary, and Rao, Jasti S., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 3 from Urokinase Plasminogen Activator Receptor and/or Matrix Metalloproteinase-9 Inhibition Induces Apoptosis Signaling through Lipid Rafts in Glioblastoma Xenograft Cells

Author

Chetty, Chandramu, primary, Lakka, Sajani S., primary, Bhoopathi, Praveen, primary, Gondi, Christopher S., primary, Veeravalli, Krishna Kumar, primary, Fassett, Daniel, primary, Klopfenstein, Jeffrey D., primary, Dinh, Dzung H., primary, Gujrati, Meena, primary, and Rao, Jasti S., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results